Vir Biotechnology Initiates ECLIPSE 3 Trial in Registrational Program for Chronic Hepatitis Delta

Reuters

08/06

<a href="https://laohu8.com/S/VIR">Vir Biotechnology</a> Initiates ECLIPSE 3 Trial in Registrational Program for Chronic Hepatitis Delta

Vir Biotechnology Inc. has announced the successful initiation of all trials in its ECLIPSE registrational program for chronic hepatitis delta $(CHD)$. The company reported the enrollment of the first participant in ECLIPSE 3, a Phase 2b trial that aims to compare the combination treatment of tobevibart and elebsiran with bulevirtide in CHD patients. The ECLIPSE 3 trial, along with the other trials in the program, is designed to provide supportive data for establishing access and reimbursement in key markets. The results of these trials have not yet been presented. The combination therapy of tobevibart and elebsiran has received several designations from regulatory agencies, highlighting its potential in addressing the unmet medical needs in CHD.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250806509549) on August 06, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2557743833"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557743833\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557743833?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-06 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557743833","market":"nz","top_or_hot":-1,"title":"Vir Biotechnology Initiates ECLIPSE 3 Trial in Registrational Program for Chronic Hepatitis Delta","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> Initiates ECLIPSE 3 Trial in Registrational Program for Chronic Hepatitis Delta\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vir Biotechnology Inc. has announced the successful initiation of all trials in its ECLIPSE registrational program for chronic hepatitis delta <a href=\"https://laohu8.com/S/CHD\">$(CHD)$</a>. The company reported the enrollment of the first participant in ECLIPSE 3, a Phase 2b trial that aims to compare the combination treatment of tobevibart and elebsiran with bulevirtide in CHD patients. The ECLIPSE 3 trial, along with the other trials in the program, is designed to provide supportive data for establishing access and reimbursement in key markets. The results of these trials have not yet been presented. The combination therapy of tobevibart and elebsiran has received several designations from regulatory agencies, highlighting its potential in addressing the unmet medical needs in CHD.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250806509549) on August 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vir Biotechnology Initiates ECLIPSE 3 Trial in Registrational Program for Chronic Hepatitis Delta</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir Biotechnology Initiates ECLIPSE 3 Trial in Registrational Program for Chronic Hepatitis Delta\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-06 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> Initiates ECLIPSE 3 Trial in Registrational Program for Chronic Hepatitis Delta\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vir Biotechnology Inc. has announced the successful initiation of all trials in its ECLIPSE registrational program for chronic hepatitis delta <a href=\"https://laohu8.com/S/CHD\">$(CHD)$</a>. The company reported the enrollment of the first participant in ECLIPSE 3, a Phase 2b trial that aims to compare the combination treatment of tobevibart and elebsiran with bulevirtide in CHD patients. The ECLIPSE 3 trial, along with the other trials in the program, is designed to provide supportive data for establishing access and reimbursement in key markets. The results of these trials have not yet been presented. The combination therapy of tobevibart and elebsiran has received several designations from regulatory agencies, highlighting its potential in addressing the unmet medical needs in CHD.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250806509549) on August 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4535","symbol_name":"淡马锡持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nNDL931KNR:1","article_id":"2557743833","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557743833","pubTimestamp":1754481935,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vir Biotechnology Inc. has announced the successful initiation of all trials in its ECLIPSE registrational program for chronic hepatitis delta . The company reported the enrollment of the first participant in ECLIPSE 3, a Phase 2b trial that aims to compare the combination treatment of tobevibart and elebsiran with bulevirtide in CHD patients. The ECLIPSE 3 trial, along with the other trials in the program, is designed to provide supportive data for establishing access and reimbursement in key markets. The results of these trials have not yet been presented. The combination therapy of tobevibart and elebsiran has received several designations from regulatory agencies, highlighting its potential in addressing the unmet medical needs in CHD.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be int","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4535":"淡马锡持仓","BK4568":"美国抗疫概念","VIR":"Vir Biotechnology, Inc.","BK4585":"ETF&股票定投概念","BK4139":"生物科技"},"translate_title":"Vir Biotechnology在慢性δ型肝炎注册计划中启动ECLIPSE 3试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIR":0.9},"content_text":"Vir Biotechnology Initiates ECLIPSE 3 Trial in Registrational Program for Chronic Hepatitis Delta\n    \n\n        Vir Biotechnology Inc. has announced the successful initiation of all trials in its ECLIPSE registrational program for chronic hepatitis delta $(CHD)$. The company reported the enrollment of the first participant in ECLIPSE 3, a Phase 2b trial that aims to compare the combination treatment of tobevibart and elebsiran with bulevirtide in CHD patients. The ECLIPSE 3 trial, along with the other trials in the program, is designed to provide supportive data for establishing access and reimbursement in key markets. The results of these trials have not yet been presented. The combination therapy of tobevibart and elebsiran has received several designations from regulatory agencies, highlighting its potential in addressing the unmet medical needs in CHD.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250806509549) on August 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}